Harmony Biosciences
HRMY
217 hedge funds and large institutions have $1.68B invested in Harmony Biosciences in 2023 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 84 increasing their positions, 79 reducing their positions, and 52 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 79
0.57% less ownership
Funds ownership: 86.65% → 86.07% (-0.57%)
10% less funds holding
Funds holding: 242 → 217 (-25)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
40% less capital invested
Capital invested by funds: $2.78B → $1.68B (-$1.1B)
40% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 52
52% less call options, than puts
Call options by funds: $4.05M | Put options by funds: $8.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$58.5M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$21.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$13.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$56.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$32.9M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$29.4M |
| 4 |
PA
Perceptive Advisors
New York
|
-$14.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.1M |
HRMY Hedge Fund Activity: Q1 2023 in Review
217 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q1 2023, worth a combined $1.68B — down 40% from $2.78B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of HRMY and 31 opened new positions — a net loss of 21 holders — while 79 trimmed existing stakes and 84 added.
The largest buyer was Adage Capital Partners, adding an estimated $58.5M. The largest seller was Janus Henderson Group, cutting an estimated $56.5M.
- 217 institutional investors held Harmony Biosciences (HRMY) as of Q1 2023, down from 242 in Q4 2022.
- Funds reported $1.68B of Harmony Biosciences stock for Q1 2023, down 40% quarter-over-quarter.
- 31 funds opened new Harmony Biosciences positions in Q1 2023 and 52 closed out, a net change of -21 holders.
- The largest Harmony Biosciences buyer in Q1 2023 was Adage Capital Partners, an estimated $58.5M added.
- The largest Harmony Biosciences seller in Q1 2023 was Janus Henderson Group, an estimated $56.5M sold.
Based on aggregated 13F filings for Q1 2023.